Rogaratinib Achieves 41.7% Response Rate in SDH-Deficient GIST, Demonstrating Breakthrough Efficacy for Previously Untreatable Tumor Subtype
Key Insights
A multicenter phase 2 trial of rogaratinib in SDH (search)-deficient gastrointestinal stromal tumors (search) achieved a 41.7% objective response rate, dramatically exceeding the 2.0% response rate seen with standard tyrosine kinase inhibitors.
The study enrolled 24 patients and demonstrated a median progression-free survival of 31.0 months with a disease control rate exceeding 91%, representing unprecedented efficacy in this rare tumor subtype.
The trial's success validates targeting epigenetically-driven FGFR (search) pathway activation in SDH (search)-deficient tumors, potentially establishing a new treatment paradigm for this previously treatment-resistant disease.
A multicenter phase 2 trial of the pan-FGFR (search) inhibitor rogaratinib has achieved remarkable clinical activity in patients with succinate dehydrogenase (SDH (search))-deficient gastrointestinal stromal tumors (search) (GIST), delivering a 41.7% objective response rate in a tumor subtype that has historically shown minimal response to standard therapies. The results, published in Nature Medicine, represent a categorical shift in treatment outcomes for this rare but challenging malignancy.
The study enrolled 24 patients with advanced SDH-deficient GIST (search) across 11 centers in the United States from May 2021 to August 2023. Ten patients achieved confirmed partial responses per RECIST 1.1 criteria, with tumor reductions ranging from 31% to 68%. An additional 12 patients achieved stable disease, yielding a disease control rate exceeding 91%. The median progression-free survival reached 31.0 months (95% CI: 20.2 months to not reached), with nine patients remaining on treatment at the data cutoff.
Mechanistic Foundation Drives Clinical Success
The trial's design was anchored in a mechanistic understanding of SDH-deficient GIST (search) biology. These tumors, which represent approximately 7.5% of gastric GISTs, are characterized by global DNA hypermethylation that disrupts CTCF binding at insulator regions. This epigenetic rewiring collapses topologically associating domains and aberrantly activates fibroblast growth factor receptor (FGFR (search)) signaling pathways.
"The mechanistic rationale for targeting FGFR (search) emerged from a 2019 Nature study showing that global DNA hypermethylation in SDH (search)-deficient GISTs disrupts CTCF binding at insulator regions, collapsing topologically associating domains and activating oncogenic FGFR programs," the investigators noted. This biological foundation enabled biomarker-selected enrollment and provided regulatory agencies with a clear therapeutic rationale.
RNA sequencing analysis confirmed that all evaluable tumors in the trial cohort overexpressed FGF4 (search) along with multiple FGFRs, supporting an autocrine signaling loop that drives tumor growth. Notably, FGF4 was highly expressed in all tumors in the trial cohort and in all SDH (search)-deficient GISTs from prior datasets, while being largely absent in other GIST subtypes.
Dramatic Improvement Over Standard Care
The clinical impact becomes clear when compared to historical outcomes. A retrospective analysis of 87 SDH-deficient GIST (search) patients treated with tyrosine kinase inhibitors found that among 49 imatinib-treated patients, exactly one achieved a partial response—a 2.0% objective response rate that established these tumors as fundamentally TKI-resistant.
The rogaratinib trial's 41.7% response rate represents more than a 20-fold improvement over this historical benchmark. The durability of responses was equally impressive, with 12 patients (50%) remaining on study for at least one year and four patients continuing treatment beyond two years. One patient remained on treatment for more than three years at the time of data analysis.
Safety Profile Supports Long-Term Treatment
Rogaratinib was administered at 800 mg twice daily in continuous 28-day cycles. The safety profile was consistent with other FGFR (search) inhibitors, with hyperphosphatemia (96%), alopecia (58%), fatigue (54%), nausea (54%), and diarrhea (50%) being the most common adverse events. While dose reductions were required in 63% of patients, these modifications did not appear to compromise treatment efficacy.
Grade 3 toxicities occurring in two or more participants included hypertension, diarrhea, and tumor hemorrhage. Treatment discontinuation due to toxicity occurred in only four patients, with reasons including grade 2 hyperphosphatemia, grade 3 leg pain, grade 2 erythema nodosum, and worsening dry eye in a patient with underlying Sjögren's syndrome.
Pharmacokinetic analysis revealed significant drug exposure variability among patients, but this did not correlate with treatment response. Importantly, serum phosphate increases were directly correlated with rogaratinib exposure, providing pharmacodynamic confirmation of FGFR1 (search) target engagement.
Class Effect Validation in Preclinical Models
To evaluate whether the clinical activity represents a broader class effect of FGFR (search) inhibition, researchers tested multiple agents in a patient-derived xenograft model of SDH-deficient GIST (search). Pemigatinib, infigratinib, and rogaratinib all demonstrated robust, statistically significant tumor growth suppression (P < 0.0001). In contrast, the multi-targeted tyrosine kinase inhibitors sunitinib and regorafenib showed activity comparable to vehicle control.
These preclinical findings strongly support the clinical hypothesis that aberrant FGF3 (search)/4–FGFR1 (search)/2 signaling drives SDH-deficient GIST (search) growth and suggest that other selective FGFR (search) inhibitors may demonstrate similar clinical efficacy.
Biomarker Strategy Enables Precision Approach
The trial's success was enabled by rigorous biomarker selection. All patients demonstrated loss of SDHB (search) expression by immunohistochemistry, with 50% having documented SDHA (search) subunit mutations or loss of SDHA protein expression. Whole-exome sequencing confirmed SDH (search) subunit alterations in the majority of tumors, with 12 SDHA, 5 SDHB, and 2 SDHC alterations identified.
Notably, objective responses were observed across all SDH (search) molecular subsets, suggesting that patients with SDH-deficient GIST (search) may benefit from FGFR (search) inhibition regardless of specific mutational status. The two patients with primary progressive disease harbored unique genetic alterations associated with aggressive tumor phenotypes, including chromosome 5p gain and concurrent TP53 and ATRX loss-of-function mutations.
Regulatory and Development Implications
The trial's design anticipated the regulatory pathway for rare tumor indications. The 24-patient enrollment was constrained by epidemiology rather than design limitations, as SDH-deficient GIST (search) comprises less than 8% of gastric GISTs and predominantly affects pediatric and young adult populations.
The study's primary endpoint of objective response rate assessed by RECIST 1.1 prioritized regulatory legibility over academic novelty. The robust efficacy signal—a 41.7% response rate against a 2.0% historical comparator in a mechanistically homogeneous population—aligns with the evidentiary structure that FDA's accelerated approval frameworks were designed to accommodate.
However, rogaratinib is no longer being developed for clinical use, highlighting the importance of evaluating other commercially available FGFR (search) inhibitors in this indication. The preclinical validation of class effect activity provides strong rationale for pursuing clinical development with alternative agents.
Broader Impact on Epigenetic Oncology
The rogaratinib trial demonstrates that epigenetic mechanisms of oncogene activation can be effectively targeted through receptor tyrosine kinase inhibition. This approach differs from direct epigenetic therapies targeting DNA methyltransferases or chromatin-modifying enzymes and represents a novel strategy for addressing methylation-driven cancers.
Given the frequency of methylation changes across human cancers, the investigators anticipate that systematic methylation profiling of tumor cohorts will identify additional aberrations that activate targetable oncogenic programs or confer specific therapeutic vulnerabilities.
The study establishes a template for biomarker-driven rare tumor trials, demonstrating that mechanistically grounded hypotheses can generate registrational-quality datasets even in small patient populations. For SDH-deficient GIST (search) patients, these results offer the first meaningful therapeutic advance in a disease that has remained largely treatment-resistant since the advent of targeted therapy in oncology.